OPTIMIZATION OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE


如何引用文章

全文:

详细

The numerous studies have shown that cardiovascular disease and non-alcoholic fatty liver disease (NAFLD) are widespread in the general population and are linked by common pathogenetic mechanisms. Therefore their combination is typical for obesity and metabolic syndrome. The results of the study, whose goal was to study the clinical course, diagnosis and treatment of arterial hypertension (AH) in patients with non-alcoholic steatohepatitis (NASH - NAFLD stage) are presented. It was found that concomitant NASH leads to more severe course of arterial hypertension. It is emphasized that in patients with arterial hypertension and NAFLD comprehensive approach to treatment, aimed at the various components of metabolic syndrome is justified. In addition to antihypertensive treatment, drugs improving liver function (essential phospholipids, ursodeoxycholic acid), lipid-lowering drugs (statins), and, if necessary, hypoglycemic agents (metformin), should be used.

参考

  1. Bellentani S, 2009, EASL Congress abstracts, p. 26-27.
  2. El-Serag H, 2009, EASL Congress abstracts, p. 28.
  3. Perseghin G, 2009, EASL Congress abstracts, p. 36.
  4. Mofrad P, Contos MJ, Haque, M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
  5. Prati D, Taioli E, Zanella A, Della Torre E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
  6. Ruttmann E, Brant LJ, Concin H, et al. γ-Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality. Circulation 2005;112:2130-37.
  7. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
  8. Lupsor M, Badea R. Imaging diagnosis and quantification of hepatic steatosis: is it an accepted alternative to needle biopsy? Romanian J Gastroenterol 2005;4(14):419-25.
  9. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Современные возможности эластометрии, фибро- и акти-теста в диагностике фиброза печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2008. Т. 18. № 4. С. 43-52.
  10. Напалков Д.А. Новые диагностические критерии метаболического синдрома Международной Федерации Сахарного Диабета (IDF) 2005 года // Эффективная фармакотерапия. 2006. № 1. С. 32-33.
  11. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock. J Gastroenterol Hepatol 2004;19:368-74.
  12. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996;6(23):1464-7.
  13. Lindor KD, Kowdley KV, Heathcote EJ, et al. (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
  14. Драпкина О.М., Тутнов Д.А. Особенности лечения артериальной гипертензии у больных с заболеваниями печени // Российские медицинские вести. 2008. № 3. С. 43-49.
  15. Никитин С.Г. Скриннинговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания // Российские медицинские вести. 2010. Т. XV. № 1. С. 41-46.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##